« Back
Home /
Nintedanib esylate

Nintedanib esylate

Item no.	HY-11106-500mg
Manufacturer	MedChem Express
CASRN	656247-18-6
Amount	500 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 500 mg 50 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer
Type	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68(12), 4774-4782.\|[2]Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem, 2009, 52(14), 4466-4480.\|[3]Suzuki N, et al. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts. Oncol Rep. 2016 Dec;36(6):3123-3130. Am J Respir Cell Mol Biol. 2020 Feb;62(2):178-190. \|Nano Today. 2024 Feb, 54, 102058.\|ACS Omega. 2022, 7, 21, 17658-17669.\|Acta Pharmacol Sin. 2021 Mar 2.\|Am J Respir Cell Mol Biol. 2019 Jul;61(1):74-85. \|Am J Respir Cell Mol Biol. 2021 Mar 24.\|Bioact Mater. 2024 Mar, 33, Pages 262-278.\|bioRxiv. 2024 Apr 21.\|bioRxiv. 2024 Jan 12.\|Br J Cancer. 2020 Mar;122(7):986-994.\|Cell Chem Biol. 2022 Jun 9;S2451-9456(22)00201-X.\|Curr Eye Res. 2022 Oct 19;1-12.\|Drug Dev Ind Pharm. 2024 Aug 7:1-16.\|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.\|Eur J Pharmacol. 2024 Jun 5:972:176547.\|Eur Respir J. 2025 Jan 9:2400615.\|European J Org Chem. Nov 2022\|Exp Eye Res. 2023 Mar 2;109431.\|Exp Eye Res. 2025 Feb 12:110285.\|FEBS Lett. 2024 Oct 20.\|Free Radic Biol Med. 2021 May 11;S0891-5849(21)00291-4.\|Fundam Clin Pharmacol. 2021 Feb 1.\|Harvard Medical School LINCS LIBRARY\|Int Immunopharmacol. 2022, 113: 109427.\|Int J Mol Sci. 2022 Jul 25;23(15):8193.\|Int J Mol Sci. 2023, 24(2), 1475.\|Int J Ophthalmol. 2022 Jun 18;15(6):914-923.\|Integr Biol (Camb). 2022 Feb 19;zyac001.\|J Cell Biochem. 2020 Mar;121(3):2343-2353.\|J Ethnopharmacol. 2023 May 17;116633.\|J Mol Struct. 2016 Jul 5; 1115:171-179.\|J Nat Prod. 2019 May 24;82(5):1331-1337.\|J Ophthalmol. 2023 Apr 28.\|J Pharmacol Exp Ther. 2019 Jun;369(3):511-522.\|J Photochem Photobiol B. 2016 Feb 5;157:70-76. \|Life Sci. 2022 Sep 10;120950.\|Lung Cancer. 2023 Jun, 180, 107219.\|medRxiv. 2024 Jun 28.\|Nat Mach Intell. 2020 Jun.\|Oncol Lett. 2024 Jan 25.\|Oncol Rep. 2016 Dec;36(6):3123-3130.\|Patent. US20220257531A1.\|PLoS One. 2019 Aug 6;14(8):e0218632.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Research Square Print. September 14th, 2022.\|Sci Adv. 2022 Jun 17;8(24):eabn4564.\|Sci Rep. 2018 Jun 22;8(1):9540. \|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Sci Transl Med. 7 Jul 2022.\|Small. 2024 Jul 25:e2403428.\|SSRN. 2023 May 8.\|Stem Cell Res Ther. 2020 Nov 25;11(1):496.\|Virology. 2023 Jun 21.
Smiles	O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN(C)CC4)=O)C=C3)/C5=CC=CC=C5)OC.CCS(=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BIBF 1120 (esylate)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	FGFR; PDGFR; VEGFR
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	649.76
Product Description	Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 66.67 mg/mL (ultrasonic)\|Ethanol: 3.08 mg/mL (ultrasonic)\|H2O: 16.67 mg/mL (ultrasonic)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Isoform	FGFR1; FGFR2; FGFR3; PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-11106-500mg-safety-datasheet.pdf